Genovis AB (publ.) Total Liabilities
Genovis AB (publ.) total liabilities. Based on the latest financial reports, Genovis AB (publ.) (GENO) has total liabilities worth Skr106.41 Million SEK (≈ $11.45 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Genovis AB (publ.) to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genovis AB (publ.) (2008–2025)
Total liabilities of Genovis AB (publ.) from 2008 to 2025. This chart illustrates how Genovis AB (publ.)'s total liabilities have evolved over time, based on quarterly financial data. Explore Genovis AB (publ.) long-term investment allocation to see how much of total assets are deployed in long-term investments.
Genovis AB (publ.) Competitors by Total Liabilities
The table below lists competitors of Genovis AB (publ.) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Motorcycle Holdings Ltd
AU:MTO
|
Australia | AU$236.97 Million |
|
Can2 Termik AS
IS:CANTE
|
Turkey | TL4.08 Billion |
|
Han Kook Capital Co. Ltd
KQ:023760
|
Korea | ₩4.50 Trillion |
|
Eugene Corporation
KQ:023410
|
Korea | ₩1.32 Trillion |
|
Cristales
SN:CRISTALES
|
Chile | CL$356.92 Billion |
|
Ilshin Spinnin
KO:003200
|
Korea | ₩171.07 Billion |
|
Repro Med Systems Inc
NASDAQ:KRMD
|
USA | $9.91 Million |
|
Link Net Tbk
JK:LINK
|
Indonesia | Rp10.81 Trillion |
Liability Composition Analysis (2008–2025)
This chart breaks down Genovis AB (publ.)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENO asset base.
Liquidity & Leverage Metrics
Genovis AB (publ.) Total Liabilities Ratios Explained
Genovis AB (publ.) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 5.81 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genovis AB (publ.)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genovis AB (publ.) (2008–2025)
The table below shows the annual total liabilities of Genovis AB (publ.) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr106.41 Million ≈ $11.45 Million |
+7.01% |
| 2024-12-31 | Skr99.44 Million ≈ $10.70 Million |
+1.42% |
| 2023-12-31 | Skr98.05 Million ≈ $10.55 Million |
+294.27% |
| 2022-12-31 | Skr24.87 Million ≈ $2.68 Million |
-10.41% |
| 2021-12-31 | Skr27.76 Million ≈ $2.99 Million |
+42.47% |
| 2020-12-31 | Skr19.48 Million ≈ $2.10 Million |
+45.14% |
| 2019-12-31 | Skr13.42 Million ≈ $1.44 Million |
+14.18% |
| 2018-12-31 | Skr11.76 Million ≈ $1.27 Million |
+44.80% |
| 2017-12-31 | Skr8.12 Million ≈ $873.71K |
+28.74% |
| 2016-12-31 | Skr6.31 Million ≈ $678.66K |
-22.07% |
| 2015-12-31 | Skr8.09 Million ≈ $870.86K |
+62.52% |
| 2014-12-31 | Skr4.98 Million ≈ $535.83K |
-40.46% |
| 2013-12-31 | Skr8.36 Million ≈ $900.00K |
+84.81% |
| 2012-12-31 | Skr4.53 Million ≈ $487.00K |
+31.88% |
| 2011-12-31 | Skr3.43 Million ≈ $369.28K |
+32.70% |
| 2010-12-31 | Skr2.59 Million ≈ $278.29K |
-33.73% |
| 2009-12-31 | Skr3.90 Million ≈ $419.91K |
-53.23% |
| 2008-12-31 | Skr8.34 Million ≈ $897.78K |
-- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more